Next Article in Journal
Synergistic Autophagy Effect of miR-212-3p in Zoledronic Acid-Treated In Vitro and Orthotopic In Vivo Models and in Patient-Derived Osteosarcoma Cells
Next Article in Special Issue
Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy
Previous Article in Journal
Mitigating Effect of 1-Palmitoyl-2-Linoleoyl-3-Acetyl-Rac-Glycerol (PLAG) on a Murine Model of 5-Fluorouracil-Induced Hematological Toxicity
Previous Article in Special Issue
CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker
Article

The Gasdermin E Gene Has Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types

1
Centre of Medical Genetics, University of Antwerp and Antwerp University Hospital, Prins Boudewijnlaan 43, 2650 Edegem, Belgium
2
Centre for Oncological Research, University of Antwerp and Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
3
StatUa Centre for Statistics, University of Antwerp, 2000 Antwerp, Belgium
4
Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(11), 1810; https://doi.org/10.3390/cancers11111810
Received: 21 October 2019 / Revised: 4 November 2019 / Accepted: 6 November 2019 / Published: 18 November 2019
(This article belongs to the Special Issue New Biomarkers in Cancers)
Due to the elevated rates of incidence and mortality of cancer, early and accurate detection is crucial for achieving optimal treatment. Molecular biomarkers remain important screening and detection tools, especially in light of novel blood-based assays. DNA methylation in cancer has been linked to tumorigenesis, but its value as a biomarker has not been fully explored. In this study, we have investigated the methylation patterns of the Gasdermin E gene across 14 different tumor types using The Cancer Genome Atlas (TCGA) methylation data (N = 6502). We were able to identify six CpG sites that could effectively distinguish tumors from normal samples in a pan-cancer setting (AUC = 0.86). This combination of pan-cancer biomarkers was validated in six independent datasets (AUC = 0.84–0.97). Moreover, we tested 74,613 different combinations of six CpG probes, where we identified tumor-specific signatures that could differentiate one tumor type versus all the others (AUC = 0.79–0.98). In all, methylation patterns exhibited great variation between cancer and normal tissues, but were also tumor specific. Our analyses highlight that a Gasdermin E methylation biomarker assay, not only has the potential for being a methylation-specific pan-cancer detection marker, but it also possesses the capacity to discriminate between different types of tumors. View Full-Text
Keywords: DNA methylation; biomarker; pan-cancer; tumor-specific; Gasdermin E; detection DNA methylation; biomarker; pan-cancer; tumor-specific; Gasdermin E; detection
Show Figures

Figure 1

MDPI and ACS Style

Ibrahim, J.; Op de Beeck, K.; Fransen, E.; Peeters, M.; Van Camp, G. The Gasdermin E Gene Has Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types. Cancers 2019, 11, 1810. https://doi.org/10.3390/cancers11111810

AMA Style

Ibrahim J, Op de Beeck K, Fransen E, Peeters M, Van Camp G. The Gasdermin E Gene Has Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types. Cancers. 2019; 11(11):1810. https://doi.org/10.3390/cancers11111810

Chicago/Turabian Style

Ibrahim, Joe, Ken Op de Beeck, Erik Fransen, Marc Peeters, and Guy Van Camp. 2019. "The Gasdermin E Gene Has Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types" Cancers 11, no. 11: 1810. https://doi.org/10.3390/cancers11111810

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop